Jerry Gurwitz to Primary Prevention
This is a "connection" page, showing publications Jerry Gurwitz has written about Primary Prevention.
Connection Strength
2.369
-
Singh S, Zieman S, Go AS, Fortmann SP, Wenger NK, Fleg JL, Radziszewska B, Stone NJ, Zoungas S, Gurwitz JH. Statins for Primary Prevention in Older Adults-Moving Toward Evidence-Based Decision-Making. J Am Geriatr Soc. 2018 11; 66(11):2188-2196.
Score: 0.564
-
Gurwitz JH, Go AS, Fortmann SP. Use of Statins in Adults Older Than 75 Years-Reply. JAMA. 2017 03 14; 317(10):1081.
Score: 0.507
-
Gurwitz JH, Go AS, Fortmann SP. Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence. JAMA. 2016 Nov 15; 316(19):1971-1972.
Score: 0.496
-
Singh S, Go AS, Wenger NK, Zoungas S, Gurwitz JH. Reply to: Statins for Primary Prevention in Older Adults. J Am Geriatr Soc. 2019 04; 67(4):857-858.
Score: 0.144
-
Greenlee RT, Go AS, Peterson PN, Cassidy-Bushrow AE, Gaber C, Garcia-Montilla R, Glenn KA, Gupta N, Gurwitz JH, Hammill SC, Hayes JJ, Kadish A, Magid DJ, McManus DD, Multerer D, Powers JD, Reifler LM, Reynolds K, Schuger C, Sharma PP, Smith DH, Suits M, Sung SH, Varosy PD, Vidaillet HJ, Masoudi FA. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network. J Am Heart Assoc. 2018 03 26; 7(7).
Score: 0.136
-
Bansal N, Szpiro A, Reynolds K, Smith DH, Magid DJ, Gurwitz JH, Masoudi F, Greenlee RT, Tabada GH, Sung SH, Dighe A, Go AS. Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease. JAMA Intern Med. 2018 03 01; 178(3):390-398.
Score: 0.135
-
Peterson PN, Greenlee RT, Go AS, Magid DJ, Cassidy-Bushrow A, Garcia-Montilla R, Glenn KA, Gurwitz JH, Hammill SC, Hayes J, Kadish A, Reynolds K, Sharma P, Smith DH, Varosy PD, Vidaillet H, Zeng CX, Normand ST, Masoudi FA. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators. J Am Heart Assoc. 2017 Nov 09; 6(11).
Score: 0.133
-
Bansal N, Szpiro A, Masoudi F, Greenlee RT, Smith DH, Magid DJ, Gurwitz JH, Reynolds K, Tabada GH, Sung SH, Dighe A, Cassidy-Bushrow A, Garcia-Montilla R, Hammill S, Hayes J, Kadish A, Sharma P, Varosy P, Vidaillet H, Go AS. Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators. Heart. 2017 04; 103(7):529-537.
Score: 0.123
-
Masoudi FA, Go AS, Magid DJ, Cassidy-Bushrow AE, Doris JM, Fiocchi F, Garcia-Montilla R, Glenn KA, Goldberg RJ, Gupta N, Gurwitz JH, Hammill SC, Hayes JJ, Jackson N, Kadish A, Lauer M, Miller AW, Multerer D, Peterson PN, Reifler LM, Reynolds K, Saczynski JS, Schuger C, Sharma PP, Smith DH, Suits M, Sung SH, Varosy PD, Vidaillet HJ, Greenlee RT. Longitudinal study of implantable cardioverter-defibrillators: methods and clinical characteristics of patients receiving implantable cardioverter-defibrillators for primary prevention in contemporary practice. Circ Cardiovasc Qual Outcomes. 2012 Nov; 5(6):e78-85.
Score: 0.094
-
Hajduk AM, Gurwitz JH, Tabada G, Masoudi FA, Magid DJ, Greenlee RT, Sung SH, Cassidy-Bushrow AE, Liu TI, Reynolds K, Smith DH, Fiocchi F, Goldberg R, Gill TM, Gupta N, Peterson PN, Schuger C, Vidaillet H, Hammill SC, Allore H, Go AS. Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter-Defibrillator Therapies. J Am Geriatr Soc. 2019 07; 67(7):1370-1378.
Score: 0.036